Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
OBJECTIVE
It was the aim of this study to test the hypothesis that the voltage-gated sodium channel gene SCN2A R19K polymorphism confers liability to oxaliplatin-induced peripheral neuropathy (OXLIPN).


METHODS
Sixty-two patients with advanced colorectal cancer were genotyped, using allele-specific primers and SYBR green in real-time polymerase chain reaction. All patients had received adjuvant oxalipla-tin-based chemotherapy. The severity of OXLIPN was defined by means of the clinical total neuropathy score. Following the discontinuation of treatment, 36/62 patients (58.1%) developed OXLIPN. Grade I neurotoxicity was revealed in 14 (38.9%) patients and grade II neurotoxicity in 22 (61.1%) patients.


RESULTS
From patients without OXLIPN (n = 26), 80.8% (n = 21) were homozygous for G, 19.2% (n = 5) were heterozygous (AG) and none was homozygous for A. The corresponding percentages for patients developing any grade of OXLIPN (n = 36) were similar. Likewise, among patients experiencing OXLIPN, insignificant differences in R19K genotypes were revealed between those with grade I versus grade II neurotoxicity.


CONCLUSIONS
Our study failed to provide evidence to support a causal relationship between the SCN2A R19K polymorphism and OXLIPN.
Argyriou
Andreas A
AA
Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Rion-Patras, Greece.
Antonacopoulou
Anna G
AG
Scopa
Chrisoula D
CD
Kottorou
Anastasia
A
Kominea
Athina
A
Peroukides
Stavros
S
Kalofonos
Haralabos P
HP
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D062551:NAV1.2 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011110:Polymorphism, Genetic; D015222:Sodium Channels / Q000235:genetics*
D000970:Antineoplastic Agents; D062551:NAV1.2 Voltage-Gated Sodium Channel; D009419:Nerve Tissue Proteins; D009944:Organoplatinum Compounds; C568251:SCN2A protein, human; D015222:Sodium Channels; D000077150:Oxaliplatin